title: Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations.
abstract: BACKGROUND
  Mutations in the presenilin-1 gene (PS1) account for a majority of patients with early-onset familial AD. However, the clinical indications and algorithms for genetic testing in dementia are still evolving.
  
  
  METHODS
  The entire open reading frame of the PS1 gene was sequenced in a series of 414 consecutive patients referred for diagnostic testing, including 372 patients with AD and 42 asymptomatic persons with a strong family history of AD.
  
  
  RESULTS
  Forty-eight independent patients screened had a PS1 mutation including 21 novel mutations. In addition, 3% of subjects (11/413) had a known polymorphism, the Glu318Gly substitution. The majority of the mutations were missense substitutions but there were three insertions and Delta exon 10 mutation. With six exceptions (codons 35, 178, 352, 354, 358, and 365) most of the mutations occurred at residues conserved in the homologous PS2 gene or in PS1 of other species.
  
  
  CONCLUSIONS
  Eleven percent of a referral-based series of patients with AD can be explained by coding sequence mutations in the PS1 gene. The high frequency of PS1 mutations in this study indicates that screening for PS1 mutations in AD is likely to be successful, especially when directed at patients with a positive family history with onset before 60 years (90% of those with PS1 mutations were affected by age 60 years). This will also have significance for the secondary identification of at-risk relatives who might be candidates for future prophylactic therapies for AD.
authors.affiliation: Centre for Research in Neurodegenerative Diseases and Division of Neurology, Department of Medicine, The University Health Network, Toronto, Ontario, Canada. ekaterina.rogaeva@utoronto.ca
authors.forename: E A
authors.initials: EA
authors.lastname: Rogaeva
authors.forename: K C
authors.initials: KC
authors.lastname: Fafel
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Song
authors.forename: H
authors.initials: H
authors.lastname: Medeiros
authors.forename: C
authors.initials: C
authors.lastname: Sato
authors.forename: Y
authors.initials: Y
authors.lastname: Liang
authors.forename: E
authors.initials: E
authors.lastname: Richard
authors.forename: E I
authors.initials: EI
authors.lastname: Rogaev
authors.forename: P
authors.initials: P
authors.lastname: Frommelt
authors.forename: A D
authors.initials: AD
authors.lastname: Sadovnick
authors.forename: W
authors.initials: W
authors.lastname: Meschino
authors.forename: K
authors.initials: K
authors.lastname: Rockwood
authors.forename: M A
authors.initials: MA
authors.lastname: Boss
authors.forename: R
authors.initials: R
authors.lastname: Mayeux
authors.forename: P
authors.initials: P
authors.lastname: St  George-Hyslop
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D053764:Presenilin-1; D012017:Referral and Consultation; D016019:Survival Analysis
chemical_list: D008565:Membrane Proteins; C508853:PSEN1 protein, human; D053764:Presenilin-1